Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (96)	1/26/1999 7:13:00 PM
From: Russian Bear	Respond to of 3158

<<We should see a good day for biotechs tomorrow.>> Peter, If I may venture a guess, I predict that SEPR leads the way. RB

To: Biomaven who wrote (96)	1/26/1999 9:27:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 3158

Peter: I'm still hopeful for third-tier. Surprised? ;-) So..... it would need to be companies that are selling at a huge discount to the research in-hand, companies with a no-brainer project (yeahrightsure) or a breadth of projects moving forward. It is apparent, imo, that non-accretive acquisitions are dirt cheap. I'd say that the breadth of programs is sufficient at SNAP, SIBI and NRGN. Those are just off the top of my head. GLIA too of course, but they don't count as they're headed for profit and honorable mention for second-tier. Just coincidence that they're all neuro, or is this the sub-sector where the best bargains are to be found? Wo, was that a great last half hour of trading for biotech or what? I picked my brain for an AGPH sympathy play and came up with VIRS. I was feeling really proud until you mentioned GILD to me. :-) If you're trying to push conversation away from third-tier, just tell me to shut up. Cheers! Rick